RFPi’s technology represents multiple years’ worth of development, experience and advancement on the part of our entrepreneurial team. Here’s a look at our company’s highlights:

2020

  • Initial close on Series B offering (round is currently open)
  • Moved into new corporate office
  • Finalized agreement with Cogmedix, Westborough, MA for commercial manufacturing
  • Established engineering relationships with Nocturnal Product Development, Durham, NC, Triple Ring Technologies, Sunnyvale, CA, and Inov, Inc., Tempe AZ.
  • Operationalized the RFPi-ARMUS Cloud Repository and Surgeon Web Portal for the FIRST Study
  • Signed Nipro development agreement to expand iCertainty™ specifically for Japan and completed phase 1 and 2

2019

  • Commenced FIRST study – clinical study at Vidant Medical Center in North Carolina
  • Awarded SBIR Phase I and STTR Phase II grants totaling $1.7 million from the NIH to further develop RFPi’s technology

2018

  • Received Class II 510(k) approval from the FDA for iCertainty™ in December
  • Selected as a 2018 MedTech Innovator from among 700 presenting. 25 Midstage companies were selected.

2017

  • Signed license, development and investment agreement with Nipro Corporation for iCertainty™ in Japan
  • RFPi converts from LLC to C Corp
  • Received federal grant to study new clinical applications of iCertainty™
  • Received research loan to develop outpatient prototype of imaging system

2016

  • Final Beta prototype design and build, with OEM suppliers and GMP
  • Build of Pre-FDA clinical devices for first two clinical application areas; testing began at selected clinical sites
  • Secured $4 million in angel investor financing in September 2016

2015

  • Conducted additional experimental in vivo studies in collaboration with the ECU Department of Comparative Studies, with IACUC approval
  • Expanded potential clinical application areas with proof-proof-of-concept studies in these experimental studies
  • Conducted additional human skin blood flow and perfusion studies for image metadata analyses

2014

  • Substantially improved the image visualization algorithms, the hardware design of the system, and the image analysis algorithms
  • Tested high-speed image acquisition and analysis in a beating heart, using an improved pre-Alpha-version prototype
  • Conducted optics benchtop testing improved visualization and analysis algorithms on optics phantoms with microfluidic capacities
  • Built fully functional pre-Alpha-Plus prototype for experimental studies
  • Conducted experimental in vivo studies in collaboration with the ECU Department of Comparative Studies, with IACUC approval
  • Conducted human skin blood flow and perfusion studies
  • RFPi forms LLC in May
  • Raised initial angel funding

2013

  • Continued image collection in coronary artery bypass surgery using the pre-Alpha version prototype, evaluating prototype sub-components
  • Continued image collection in other applications using improved pre-Alpha version prototype
  • Began to derive important additional information beyond flow and perfusion from the visualization image metadata

2012

  • Built the pre-Alpha-version prototype to successfully document proof of concept in the coronary artery bypass surgery setting, with IRB approval
  • Designed and tested EKG acquisition and synchronization
  • Investigated the feasibility of LSI in other clinical applications, with initial testing with the pre-Alpha-version prototype
  • Successfully documented proof of concept in the coronary artery bypass surgery setting, with IRB approval

2011

  • Refine optics benchtop testing of flow measurement of intra-lipid solution and human blood, incorporating cardiovascular pulsatile flow and cardiac cycle movement into the model
  • Conducted initial flow dynamic model testing

2010

  • Investigated the feasibility of Laser Speckle Imaging (“LSI”) for a cardiac application, in a beating heart
  • Designed laboratory experiments to quantify flow measurement
  • Conducted optics benchtop testing of flow measurement of intra-lipid solution
Back To Top